2 min read
Connect with Veristat at Bio International Convention 2026
June 22-25, 2026 – San Diego, CA
🌎 Bringing the Global Biopharma Community Together
We’re delighted to be attending...
The development of biosimilar products in the U.S. has progressed since the regulatory pathway was established as part of the Affordable Care Act. Since then, the number of active biosimilar development programs has risen steadily. The market for these products is projected to exceed 100 billion dollars by 2028.
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to learn more about the analytical and clinical science of biosimilars and their regulatory pathway.
Learning Points
- Biosimilars vs. Generics
- Demonstrating biosimilarity to a reference product
- Evaluating comparative data between a biosimilar and reference product
- Differences between regular and interchangeable biosimilars
- Key regulatory considerations for development of biosimilars in the U.S.
- Financial considerations for biosimilar development
Meet Veristat. Learn More.
Get the Latest News
Categories
- Regulatory Consulting (137)
- Regulatory Submissions (132)
- Clinical Trial Regulations (121)
- COVID-19 (46)
- Strategic Consulting (40)
- Clinical Trials (35)
- Life At Veristat (21)
- Oncology (18)
- Events (16)
- Success Stories (13)
- Clinical Operations/Monitoring (12)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Full-Service (9)
- Medical Writing (9)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Neurology/CNS (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Psychedelics (2)
- Rare Diseases (2)
- Hematology (1)
- Medical Affairs (1)
2 min read
Connect with Veristat at DIA 2026
Jun 5, 2026 Veristat Events
June 14-18, 2026 – Philadelphia, PA
Veristat is excited to join industry leaders and innovators at the DIA 2026 Global...